Publication | Open Access

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

OncologyTlr9 AgonistMedicinePhase IiiMetronomic TherapyBronchial NeoplasmFirst-line TreatmentCancer TreatmentPharmacologyRadiation OncologyLung Cancer